EAU 2020: Health-Related Quality-of-Life Analysis From KEYNOTE-426: Pembrolizumab Plus Axitinib vs Sunitinib for Advanced Renal Cell Carcinoma

(UroToday.com) As part of the “Game-changing Session 4” plenary session at the European Association of Urology (EAU) Virtual Annual Meeting, Dr. Bedke discussed health-related quality of life analysis from the KEYNOTE-426 trial. As most UroToday readers will know, the primary analysis of the KEYNOTE-426 trial demonstrated a significant survival advantage for patients with metastatic renal cell carcinoma […]

SUO – AUA 2020 Summer Webcast: Renal Replacement for Cure: Considerations in the Setting of Mandatory Nephrectomy – Transplant Perspective

(UroToday.com) As part of the Kidney Cancer Session at the 2020 Virtual Society of Urologic Oncology (SUO) Summer Webcast, Dr. Venkatesh Krishnamurthi discussed the role of mandatory nephrectomy in the setting of pre-renal transplant. Dr. Krishnamurthi is uniquely trained in both kidney transplant and urologic oncology. Dr. Krishnamurthi notes that patients receiving a renal transplant, whether from a deceased or living donor, have improved […]

SUO – AUA 2020 Summer Webcast: Three Papers in the Past Year That Have Changed My Practice: Bladder Cancer

(UroToday.com) To conclude the 2020 Society of Urologic Oncology Summer Virtual Webcast bladder cancer session, Janet Kukreja, MD, from the University of Colorado discussed three papers published this year that have changed her practice. The first paper was by Steinberg et al. entitled “Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive […]

EAU 2020: Late Toxicity and Quality of Life from GETUG-AFU 22 Study: A Randomised Phase II Trial Comparing 6 Months of Degarelix in Combination with Radiotherapy to Radiotherapy Alone for Patients with Detectable PSA After Radical Prostatectomy

(UroToday.com) The best abstract oncology session at the virtual EAU 2020 meeting featured second place winner Dr. Paul Sargos discussing late toxicity and quality of life from the GETUG-AFU 22 study. Currently, no recommendations exist for patients with immediate detectable prostate specific antigen (PSA) after radical prostatectomy. The purpose of the GETUG-AFU 22 study was […]

X